TWST Form 144 Proposed Sale: 2,041 Shares, $65,694 MV Filed Notice

Twist Bioscience Corp (TWST) submitted a Form 144 notice reporting a proposed sale of 2,041 common shares with an aggregate market value of $65,693.67, planned for 10/06/2025 on NASDAQ.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) submitted a Form 144 notice reporting a proposed sale of 2,041 common shares with an aggregate market value of $65,693.67, planned for 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and the stated nature of payment is compensation. The filer also disclosed four earlier open-market sales by the same person between 08/04/2025 and 09/08/2025, totaling 1,511 shares and gross proceeds of $41,029.46. The notice includes the usual representation that the seller is not aware of undisclosed material adverse information.

FAQ

What does the TWST Form 144 report?

The Form 144 reports a proposed sale of 2,041 common shares with an aggregate market value of $65,693.67, planned for 10/06/2025 on NASDAQ.

Why were the 2,041 shares acquired by the seller?

The shares were acquired on 10/01/2025 through restricted stock vesting and payment is listed as compensation.

Has the seller traded TWST shares recently?

Yes. The filer sold 1,511 shares across four transactions between 08/04/2025 and 09/08/2025, generating gross proceeds of $41,029.46.

On which exchange will the proposed sale occur?

The proposed sale is expected to occur on NASDAQ.

Does the filer assert there is any undisclosed material information?

By signing, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 05:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001590947
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	WERNER ROBERT F.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2041	65693.67	60360925	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Restricted Stock Vesting	Issuer			2041	10/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/04/2025	186	5275.72
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2025	238	6179.48
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	08/25/2025	853	23620.68
Robert Werner 681 Gateway Blvd South San Francisco CA 94080	Common	09/08/2025	234	6053.58

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	10/06/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gerardo Ibarra-Munoz, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert F. Werner
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)